how much tesamorelin: Frequently asked questions

Glucose elevation is the primary dose-limiting side effect, occurring in 15–20% of subjects at 2mg daily. Growth hormone is counter-regulatory to insulin, and sustained IGF-1 elevation reduces peripheral glucose uptake in some individuals. Reduce dose to 1.5mg and recheck fasting glucose at week 4. Most subjects tolerate 1.5mg without clinically significant glucose changes while maintaining IGF-1 elevation above 60 ng/mL. If glucose intolerance persists, discontinuation is typically recommended rather than further dose reduction.

No. Tesamorelin's mechanism relies on consistent daily GH pulses, not total weekly exposure. Missing one dose drops IGF-1 by approximately 15–20% within 36 hours, but doubling the next dose doesn't recover the gap. It increases acute GH spike magnitude without extending IGF-1 duration, raising the risk of transient hyperglycemia. Resume at standard 2mg the following evening. Consistent daily dosing outperforms erratic higher-dose catch-up attempts.

Verify reconstitution accuracy first. Underfilling the syringe by 0.3mL reduces dose to 1.7mg, potentially dropping below the response threshold. Confirm refrigeration compliance (vials stored above 8°C lose potency rapidly) and injection site rotation (repeated injections in scarred tissue slow absorption). If technique and storage are correct, consider baseline IGF-1 status. Subjects with naturally high baseline IGF-1 (>250 ng/mL) show blunted response to exogenous GHRH stimulation. Extending observation to week 8 before adjusting dose is standard protocol.

Discard it immediately and do not inject. Lyophilised Tesamorelin and Ipamorelin should reconstitute into a clear, colourless solution. Cloudiness indicates protein aggregation or bacterial contamination. Both render the peptide biologically inactive and unsafe. Aggregation typically results from using non-sterile water, reconstituting at room temperature instead of refrigerated, or vigorous shaking instead of gentle swirling. Always use bacteriostatic water stored at 2–8°C and swirl the vial gently until the powder dissolves completely.

No. Resume the regular schedule with the standard dose. Doubling a missed dose does not compensate for the lost GH pulse and significantly increases the risk of acute hyperglycaemia, joint pain, and water retention. GH secretion patterns are circadian; skipping one evening dose shifts the rhythm slightly but does not negate the cumulative IGF-1 elevation built over weeks. If doses are missed frequently (more than twice per week), the protocol's efficacy is compromised. Consistency matters more than compensation.

Escalate to 300 mcg of each peptide and retest IGF-1 at week 8. Non-response at 200 mcg occurs in 15–20% of subjects, often those over age 50 or with insulin resistance. Both conditions elevate somatostatin tone, which inhibits GH secretion even when GHRH and ghrelin receptors are stimulated. If IGF-1 remains unchanged at 300 mcg after another 4 weeks, verify injection technique, reconstitution accuracy, and peptide storage conditions before escalating further.

Rotate injection sites across the abdomen, thighs, and deltoids. Never inject in the same spot within 7 days. Persistent injection site redness, swelling, or hardness suggests either poor injection technique (needle inserted at too shallow an angle) or peptide pH incompatibility with subcutaneous tissue. Tesamorelin + Ipamorelin blends prepared at pH below 5.0 or above 7.5 can irritate tissue. If reactions persist despite rotation, request peptide pH testing from the supplier or switch to a different compounding source.